AUTONOMIX MEDICAL, INC. Research and Development Expense
AUTONOMIX MEDICAL, INC. (AMIX) reported Research and Development Expense of $1.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- AUTONOMIX MEDICAL, INC. research and development expense for the quarter ending 2026-06-30 was $1.51M, a 4.90% decline year-over-year.
- AUTONOMIX MEDICAL, INC. research and development expense for the quarter ending 2026-03-31 was $1.46M, a 5.99% decline year-over-year.
- AUTONOMIX MEDICAL, INC. research and development expense for the quarter ending 2025-12-31 was $1.72M, a 65.13% increase year-over-year.
- AUTONOMIX MEDICAL, INC. research and development expense for the quarter ending 2025-09-30 was $2.37M, a 101.62% increase year-over-year.
- AUTONOMIX MEDICAL, INC. research and development expense for fiscal 2026 was $7.14M, a 51.20% increase from fiscal 2025.
- AUTONOMIX MEDICAL, INC. research and development expense for fiscal 2025 was $4.72M, a 112.36% increase from fiscal 2024.
- AUTONOMIX MEDICAL, INC. research and development expense for fiscal 2024 was $2.23M, a 198.66% increase from fiscal 2023.
- AUTONOMIX MEDICAL, INC. research and development expense for fiscal 2023 was $745.00K.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.51M 10-Q · filed 2026-08-13 | $2.98M derived: sum of 2 quarters · filed 2026-08-13 | $4.70M derived: sum of 3 quarters · filed 2026-08-13 | $7.07M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-27 | $3.18M derived: sum of 2 quarters · filed 2026-05-27 | $5.55M derived: sum of 3 quarters · filed 2026-05-27 | $7.14M 10-K · filed 2026-05-27 | ||
| 2025-12-31 | $1.72M 10-Q · filed 2026-02-11 | $4.09M derived: sum of 2 quarters · filed 2026-02-11 | $5.68M 10-Q · filed 2026-02-11 | $7.24M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-09-30 | $2.37M 10-Q · filed 2025-11-12 | $3.96M 10-Q · filed 2025-11-12 | $5.51M derived: sum of 3 quarters · filed 2026-08-13 | $6.56M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $1.59M 10-Q · filed 2026-08-13 | $3.15M derived: sum of 2 quarters · filed 2026-08-13 | $4.19M derived: sum of 3 quarters · filed 2026-08-13 | $5.36M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-27 | $2.60M derived: sum of 2 quarters · filed 2026-05-27 | $3.77M derived: sum of 3 quarters · filed 2026-05-27 | $4.72M 10-K · filed 2026-05-27 | ||
| 2024-12-31 | $1.04M 10-Q · filed 2026-02-11 | $2.22M derived: sum of 2 quarters · filed 2026-02-11 | $3.17M 10-Q · filed 2026-02-11 | $3.87M derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2024-09-30 | $1.17M 10-Q · filed 2025-11-12 | $2.13M 10-Q · filed 2025-11-12 | $2.83M derived: sum of 3 quarters · filed 2025-11-12 | $3.51M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $954.00K 10-Q · filed 2025-08-13 | $1.65M derived: sum of 2 quarters · filed 2025-08-13 | $2.34M derived: sum of 3 quarters · filed 2025-08-13 | $2.81M derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $698.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | $1.39M derived: sum of 2 quarters · filed 2025-05-29 | $1.86M derived: sum of 3 quarters · filed 2025-05-29 | $2.23M 10-K · filed 2025-05-29 | ||
| 2023-12-31 | $687.00K 10-Q · filed 2025-02-13 | $601.00K 10-Q · filed 2024-02-13 | $1.16M derived: sum of 2 quarters · filed 2025-02-13 | $1.53M 10-Q · filed 2025-02-13 | $1.38M 10-Q · filed 2024-02-13 | $1.93M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-09-30 | $471.00K 10-Q · filed 2024-11-08 | $839.00K 10-Q · filed 2024-11-08 | $1.25M derived: sum of 3 quarters · filed 2024-11-08 | $1.45M derived: sum of 4 quarters · filed 2024-11-08 | ||
| 2023-06-30 | $368.00K 10-Q · filed 2024-08-13 | $775.00K derived: sum of 2 quarters · filed 2024-08-13 | $974.00K derived: sum of 3 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $407.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-31 | $606.00K derived: sum of 2 quarters · filed 2024-05-31 | $745.00K 10-K · filed 2024-05-31 | |||
| 2022-12-31 | $199.00K 10-Q · filed 2024-02-13 | $338.00K 10-Q · filed 2024-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |